NEW YORK (GenomeWeb) – PerkinElmer announced that it has priced an offering of €500 million ($554.2 million) of 1.875 percent senior notes due 2026 at an issue price of 99.118 percent of the principal amount.

The issuance is expected to close on July 19, the company said, and the notes will pay interest on an annual basis.

PerkinElmer plans to use the proceeds to reduce the amounts outstanding under its senior unsecured revolving credit facility and for general corporate purposes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.